

*AMENDMENTS TO THE CLAIMS*

This listing of claims replaces all prior versions, and listings, of claims in the application.

1. (Currently Amended) A method for the prophylactic and/or therapeutic treatment of a cancer receptor tyrosine kinase (RTK) hyperfunction induced disorder in a mammal wherein (i) the mammal comprises a mutated fibroblast growth factor receptor-4 (FGFR-4) protein, and (ii) the mutated FGFR-4 comprises at least one point mutation in the transmembrane domain of FGFR-4 that substitutes a hydrophilic amino acid for a hydrophobic amino acid, which method comprises administering to a the mammal in need thereof an effective amount of at least one inhibitor of fibroblast growth factor receptor-4 (FGFR-4) the mutated FGFR-4, wherein the cancer in the mammal said RTK hyperfunction-induced disorder is treated prophylactically and/or therapeutically.
2. (Cancelled)
3. (Currently Amended) The method of claim 2 1, wherein said cancer disorder is breast cancer, squamous cell carcinoma, glioblastoma, neuroblastoma, or uterine cancer.
4. (Original) The method of claim 1, wherein said inhibitor is a kinase-inactive receptor.
- 5.-6. (Cancelled)
7. (Currently Amended) The method of claim 6 1, wherein the at least one mutation is one or several point mutations.
- 8.-10. (Cancelled)
11. (Currently Amended) The method of claim 6 1, wherein the mutation occurs at amino acid position 388 in an FGFR-4 protein having the amino acid sequence of EMBL Gene Bank accession number X57205 the FGFR-4 molecule.
12. (Original) The method of claim 11, wherein the mutation leads to an exchange of glycine for arginine.

13. (Currently Amended) The method of claim ~~6~~ 1, wherein the mutation is a germ line mutation.

14.-29. (Cancelled)